News

FDA approves Triumeq PD formulation for pediatric treatment of HIV plus a supplemental approval for Triumeg.- ViiV Healthcare

Read time: 1 mins

Published:1st Apr 2022

ViiV Healthcare announced that the FDA has approved a new drug application (NDA) for Triumeq PD, a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine for the treatment of pediatric patients weighing 10kgs to <25 kgs with human immunodeficiency virus type 1 (hiv-1).

In addition, a supplemental new drug application (sNDA) has been approved for Triumeq tablet, lowering the minimum weight that a child with human immunodeficiency virus type 1 (HIV-1) can be prescribed this medicine to 25kgs from 40kgs.

Condition: HIV/AIDS

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

FDA approval of Dovato (dolutegravir/lamivudine) for adolescents living with HIV

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced the FDA approved Dovato (dolutegravir/lamivudine) for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato

1 mins

Drug news

FDA approves Edurant Ped (rilpivirine) for certain pediatric patients Living with HIV-1.

Johnson & Johnson announced that the FDA has approved Edurant Ped (rilpivirine) for the treatment of HIV-1 in combination with other antiretroviral therapies (ARVs) in treatment-naïve children (with HIV-1 RNA <100,000 copies ml) at least 2 years of age and weighing at least 14 kg and less than 25 kg.></100,000>

1 min

Drug news

sBLA for Trogarzo intramuscular (IM) method of administration for HIV infection is submitted to FDA

Theratechnologies Inc. a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that the Company has filed a supplemental Biologics License Application (sBLA) for an intramuscular (IM) method of administration for the maintenance dose of Trogarzo (ibalizumab-uiyk) to the FDA for review

1 min

See all news